Leo Pharma makes new push for older treatment with brand new trial concept

Four years after the launch of Enstilar, a psoriasis treatment, Leo Pharma hopes to give the product a significant lift with data for a new treatment concept using the medicine.

Photo: Leo Pharma / PR

Although Leo Pharma is repositioning itself as a developer and manufacturer of biological treatments to a larger and larger degree, the company has not turned its back on its older products.

The company has recently published data from a study involving Enstilar, a four-year old foam-based treatment for psoriasis. According to research and development director Kim Kjøller, it may be very significant not just for Enstilar, but for psoriasis treatments in general.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs